Twist Bioscience Analyst Price Targets

Wall Street analyst price targets and consensus rating for Twist Bioscience (TWST).

Price Target Range — 11 Quarters

Analyst Consensus — 13 Analysts

11Buy

1Hold

1Sell

Consensus RatingBuy# Analysts13Avg. Consensus PT$72Upside to Avg. PT-42.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 5, 2026	Piper Sandler	David Westenberg	PT Raise	Overweight	$85→$115
Aug 4, 2026	Baird	Catherine Ramsey	PT Raise	Outperform	$113→$115
Jul 14, 2026	Canaccord Genuity	Kyle Mikson	PT Raise	Buy	$90→$120
Jul 6, 2026	Evercore ISI Group	Vijay Kumar	Downgrade	Outperform→In-Line	$66→$102
Jun 29, 2026	Guggenheim	Subbu Nambi	PT Raise	Buy	$60→$107
Jun 24, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$65→$95
Jun 15, 2026	TD Cowen	Brendan Smith	PT Raise	Buy	$68→$89
Jun 15, 2026	Canaccord Genuity	Kyle Mikson	Initiate	Buy	$90
Jun 11, 2026	Piper Sandler	David Westenberg	Initiate	Overweight	$85
May 5, 2026	Leerink Partners	Puneet Souda	Upgrade	Market Perform→Outperform	$70
May 5, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$55→$65
May 5, 2026	Guggenheim	Subbu Nambi	PT Raise	Buy	$55→$60
May 5, 2026	Baird	Catherine Ramsey	PT Raise	Outperform	$50→$65
Apr 14, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$50→$55
Apr 6, 2026	Evercore ISI Group	Vijay Kumar	PT Raise	Outperform	$52→$56
Mar 30, 2026	Guggenheim	Subbu Nambi	PT Raise	Buy	$50→$55
Feb 3, 2026	Evercore ISI Group	Vijay Kumar	PT Raise	Outperform	$42→$52
Feb 3, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$39→$50
Jan 26, 2026	Guggenheim	Subbu Nambi	PT Raise	Buy	$42→$50
Jan 8, 2026	TD Cowen	Brendan Smith	PT Raise	Buy	$32→$43

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Piper Sandler Maintains Overweight on Twist Bioscience, Raises Price Target to $115

Piper Sandler analyst David Westenberg maintains Twist Bioscience (NASDAQ:TWST) with a Overweight and raises the price target from $85 to $115.

Benzinga Newsdesk

PRO
Baird Maintains Outperform on Twist Bioscience, Raises Price Target to $115

Baird analyst Catherine Ramsey maintains Twist Bioscience (NASDAQ:TWST) with a Outperform and raises the price target from $113 to $115.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Twist Bioscience, Raises Price Target to $120

Canaccord Genuity analyst Kyle Mikson maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the price target from $90 to $120.

Benzinga Newsdesk

PRO
Evercore ISI Group Downgrades Twist Bioscience to In-Line, Raises Price Target to $102

Evercore ISI Group analyst Vijay Kumar downgrades Twist Bioscience (NASDAQ:TWST) from Outperform to In-Line and raises the price target from $66 to $102.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Twist Bioscience, Raises Price Target to $107

Guggenheim analyst Subbu Nambi maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the price target from $60 to $107.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Twist Bioscience, Raises Price Target to $95

Barclays analyst Luke Sergott maintains Twist Bioscience (NASDAQ:TWST) with a Overweight and raises the price target from $65 to $95.

Benzinga Newsdesk

Twist Bioscience Corp

Twist Bioscience Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Piper Sandler Maintains Overweight on Twist Bioscience, Raises Price Target to $115

PRO
Baird Maintains Outperform on Twist Bioscience, Raises Price Target to $115

PRO
Canaccord Genuity Maintains Buy on Twist Bioscience, Raises Price Target to $120

PRO
Evercore ISI Group Downgrades Twist Bioscience to In-Line, Raises Price Target to $102

PRO
Guggenheim Maintains Buy on Twist Bioscience, Raises Price Target to $107

PRO
Barclays Maintains Overweight on Twist Bioscience, Raises Price Target to $95

People Also Watch

People Also Watch

Twist Bioscience Corp

Twist Bioscience Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROPiper Sandler Maintains Overweight on Twist Bioscience, Raises Price Target to $115

PROBaird Maintains Outperform on Twist Bioscience, Raises Price Target to $115

PROCanaccord Genuity Maintains Buy on Twist Bioscience, Raises Price Target to $120

PROEvercore ISI Group Downgrades Twist Bioscience to In-Line, Raises Price Target to $102

PROGuggenheim Maintains Buy on Twist Bioscience, Raises Price Target to $107

PROBarclays Maintains Overweight on Twist Bioscience, Raises Price Target to $95

People Also Watch

People Also Watch

PRO
Piper Sandler Maintains Overweight on Twist Bioscience, Raises Price Target to $115

PRO
Baird Maintains Outperform on Twist Bioscience, Raises Price Target to $115

PRO
Canaccord Genuity Maintains Buy on Twist Bioscience, Raises Price Target to $120

PRO
Evercore ISI Group Downgrades Twist Bioscience to In-Line, Raises Price Target to $102

PRO
Guggenheim Maintains Buy on Twist Bioscience, Raises Price Target to $107

PRO
Barclays Maintains Overweight on Twist Bioscience, Raises Price Target to $95